Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Khanna Website

Chand Khanna, D.V.M., Ph.D.

Selected Publications

1)  El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE.
Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
J. Clin. Invest. 124: 156-68, 2014.
2)  Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S, Ehrhart EJ, Charles B, Fehling H, Kumar L, Vail D, Henson M, Childress M, Kitchell B, Kingsley C, Kim S, Neff M, Davis B, Khanna C, Trent J.
Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.
PLoS ONE. 9: e90028, 2014.
3)  Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, Glynn SA, Hussain SP, Young HA, Ambs S, Wink DA.
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
Proc. Natl. Acad. Sci. U.S.A. 111: 6323-8, 2014.
4)  Mendoza A, Gharpure R, Dennis J, Webster JD, Smedley J, Khanna C.
A novel noninvasive method for evaluating experimental lung metastasis in mice.
J. Am. Assoc. Lab. Anim. Sci. 52: 584-9, 2013.
5)  Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, Flanagan AM, Tirabosco R, Andrulis IL, Wunder JS, Gokgoz N, Patiño-Garcia A, Sierrasesúmaga L, Lecanda F, Kurucu N, Ilhan IE, Sari N, Serra M, Hattinger C, Picci P, Spector LG, Barkauskas DA, Marina N, de Toledo SR, Petrilli AS, Amary MF, Halai D, Thomas DM, Douglass C, Meltzer PS, Jacobs K, Chung CC, Berndt SI, Purdue MP, Caporaso NE, Tucker M, Rothman N, Landi MT, Silverman DT, Kraft P, Hunter DJ, Malats N, Kogevinas M, Wacholder S, Troisi R, Helman L, Fraumeni JF, Yeager M, Hoover RN, Chanock SJ.
Genome-wide association study identifies two susceptibility loci for osteosarcoma.
Nat. Genet. 45: 799-803, 2013.
6)  Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Oncogene. 32: 5429-38, 2013.
7)  Guha M, Srinivasan S, Ruthel G, Kashina AK, Carstens RP, Mendoza A, Khanna C, Van Winkle T, Avadhani NG.
Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells.
Oncogene. [Epub ahead of print], 2013.
8)  Hong SH, Ren L, Mendoza A, Eleswarapu A, Khanna C.
Apoptosis resistance and PKC signaling: distinguishing features of high and low metastatic cells.
Neoplasia. 14: 249-58, 2012.
9)  Ren L, Hong SH, Chen QR, Briggs J, Cassavaugh J, Srinivasan S, Lizardo MM, Mendoza A, Xia AY, Avadhani N, Khan J, Khanna C.
Dysregulation of ezrin phosphorylation prevents metastasis and alters cellular metabolism in osteosarcoma.
Cancer Res. 72: 1001-12, 2012.
10)  Schayek H, Bentov I, Jacob-Hirsch J, Yeung C, Khanna C, Helman LJ, Plymate SR, Werner H.
Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
Horm. Metab. Res. 44: 511-9, 2012.
11)  Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY, Heinecke JL, Brueggemann E, Hines HB, Khanna C, Glynn SA, Ambs S, Wink DA.
Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation.
PLoS ONE. 7: e44081, 2012.
12)  Sahora AI, Rusk AW, Henkin J, McKeegan EM, Shi Y, Khanna C.
Prospective Study of Thrombospondin-1 Mimetic Peptides, ABT-510 and ABT-898, in Dogs with Soft Tissue Sarcoma.
J Vet Intern Med. 26: 1169-76, 2012.
13)  Bulut G, Hong S, Chen K, Beauchamp EM, Rahim S, Kosturko GW, Glasgow E, Dakshanamurthy S, Lee H, Daar I, Toretsky JA, Khanna C, Uren A.
Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells.
Oncogene. 31: 269-81, 2012.
14)  Briggs JW, Ren L, Nguyen R, Chakrabarti K, Cassavaugh J, Rahim S, Bulut G, Zhou M, Veenstra TD, Chen Q, Wei JS, Khan J, Uren A, Khanna C.
The ezrin metastatic phenotype is associated with the initiation of protein translation.
Neoplasia. 14: 297-310, 2012.
15)  Briggs J, Paoloni M, Chen QR, Wen X, Khan J, Khanna C.
A compendium of canine normal tissue gene expression.
PLoS ONE. 6: e17107, 2011.
16)  Vail DM, von Euler H, Rusk AW, Barber L, Clifford C, Elmslie R, Fulton L, Hirschberger J, Klein M, London C, Martano M, McNiel EA, Morris JS, Northrup N, Phillips B, Polton G, Post G, Rosenberg M, Ruslander D, Sahora A, Siegel S, Thamm D, Westberg S, Winter J, Khanna C.
A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs.
J. Vet. Intern. Med. 26: 598-607, 2011.
17)  Osborne TS, Khanna C.
A review of the association between osteosarcoma metastasis and protein translation.
J. Comp. Pathol. 146: 132-42, 2011.
18)  Kirby GM, Mackay A, Grant A, Woods P, McEwen B, Khanna C, Macri J, Hayes MA, Stalker M.
Concentration of lipocalin region of collagen XXVII alpha 1 in the serum of dogs with hemangiosarcoma.
J. Vet. Intern. Med. 25: 497-503, 2011.
19)  Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, Khan J, Helman LJ.
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Neoplasia. 13: 145-53, 2011.
20)  Osborne TS, Ren L, Healey JH, Shapiro LQ, Chou AJ, Gorlick RG, Hewitt SM, Khanna C.
Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray.
J. Pediatr. Hematol. Oncol. 33: 524-8, 2011.
21)  Silver M, Rusk A, Phillips B, Beck E, Jankowski M, Philibert J, Hahn K, Hershey E, McKeegan E, Bauch J, Krivoshik A, Khanna C.
Evaluation of the oral antimitotic agent (ABT-751) in dogs with lymphoma.
J. Vet. Intern. Med. 26: 349-54, 2011.
22)  Grohar PJ, Woldemichael GM, Griffin LB, Mendoza A, Chen QR, Yeung C, Currier DG, Davis S, Khanna C, Khan J, McMahon JB, Helman LJ.
Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
J. Natl. Cancer Inst. 103: 962-78, 2011.
23)  McCleese JK, Bear MD, Kulp SK, Mazcko C, Khanna C, London CA.
Met interacts with EGFR and Ron in canine osteosarcoma.
Vet Comp Oncol. 11: 124-39, 2011.
24)  Hong SH, Osborne T, Ren L, Briggs J, Mazcko C, Burkett SS, Khanna C.
Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells.
Vet Comp Oncol. 9: 207-18, 2011.
25)  Withrow SJ, Khanna C.
Bridging the gap between experimental animals and humans in osteosarcoma.
Cancer Treat. Res. 152: 439-46, 2010.
26)  Wu Y, Brodt P, Sun H, Mejia W, Novosyadlyy R, Nunez N, Chen X, Mendoza A, Hong SH, Khanna C, Yakar S.
Insulin-like growth factor-I regulates the liver microenvironment in obese mice and promotes liver metastasis.
Cancer Res. 70: 57-67, 2010.
27)  Mendoza A, Hong SH, Osborne T, Khan MA, Campbell K, Briggs J, Eleswarapu A, Buquo L, Ren L, Hewitt SM, Dakir el-H, Garfield S, Walker R, Merlino G, Green JE, Hunter KW, Wakefield LM, Khanna C.
Modeling metastasis biology and therapy in real time in the mouse lung.
J. Clin. Invest. 120: 2979-88, 2010.
28)  Gordon IK, Khanna C.
Modeling opportunities in comparative oncology for drug development.
ILAR J. 51: 214-20, 2010.
29)  Hawkins E, Hall J, Cohn L, Buechner-Maxwell V, Oyama M, Barton MH, Olby N, Khanna C, Marks S, McFarlane D, Toll J.
More on cultivating veterinarian-scientists.
J. Am. Vet. Med. Assoc. 237: 1367, 2010.
30)  Gorlick R, Khanna C.
J. Bone Miner. Res. 25: 683-91, 2010.
31)  Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, Vail DM, Nuckolls K, Osborne T, Yalkowsy S, Gustafson D, Yu Y, Cao L, Khanna C.
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.
PLoS ONE. 5: e11013, 2010.
32)  Vail DM, Michels GM, Khanna C, Selting KA, London CA.
Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.
Vet Comp Oncol. 8: 28-37, 2010.
33)  Paoloni M, Lana S, Thamm D, Mazcko C, Withrow S.
The creation of the Comparative Oncology Trials Consortium Pharmacodynamic Core: Infrastructure for a virtual laboratory.
Vet. J. 185: 88-9, 2010.
34)  Sahora A, Khanna C.
A survey of evidence in the Journal of Veterinary Internal Medicine oncology manuscripts from 1999 to 2007.
J. Vet. Intern. Med. 24: 51-6, 2009.
35)  Wan X, Kim SY, Guenther LM, Mendoza A, Briggs J, Yeung C, Currier D, Zhang H, Mackall C, Li W, Tuan RS, Deyrup AT, Khanna C, Helman L.
Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin.
Oncogene. 28: 3401-11, 2009.
36)  Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, Hewitt S, Triche T, Meltzer P, Khanna C.
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.
BMC Genomics. 10: 625, 2009.
37)  Khanna C, Gordon I.
Catching cancer by the tail: new perspectives on the use of kinase inhibitors.
Clin. Cancer Res. 15: 3645-7, 2009.
38)  Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, Kim M, Wang D, Moody K, Gorlick R.
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma.
Cancer. 115: 5243-50, 2009.
39)  Khanna C, London C, Vail D, Mazcko C, Hirschfeld S.
Guiding the optimal translation of new cancer treatments from canine to human cancer patients.
Clin. Cancer Res. 15: 5671-7, 2009.
40)  Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, Fang J, Kim SY, Yeung C, Helman LJ, Mendoza A, Ngo V, Staudt LM, Wei JS, Khanna C, Catchpoole D, Qualman SJ, Hewitt SM, Merlino G, Chanock SJ, Khan J.
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
J. Clin. Invest. 119: 3395-407, 2009.
41)  Leaner VD, Chick JF, Donninger H, Linniola I, Mendoza A, Khanna C, Birrer MJ.
Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma.
Am. J. Pathol. 174: 265-75, 2009.
42)  Mushinski JF, Nguyen P, Stevens LM, Khanna C, Lee S, Chung EJ, Lee MJ, Kim YS, Linehan WM, Horisberger MA, Trepel JB.
Inhibition of tumor cell motility by the interferon-inducible GTPase MxA.
J. Biol. Chem. 284: 15206-14, 2009.
43)  Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti SK.
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature.
PLoS ONE. 4: e4972, 2009.
44)  Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C.
Murine osteosarcoma primary tumour growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I.
Int. J. Cancer. 124: 2042-9, 2009.
45)  Mendoza M, Khanna C.
Revisiting the seed and soil in cancer metastasis.
Int. J. Biochem. Cell Biol. 41: 1452-62, 2009.
46)  Ren L, Hong SH, Cassavaugh J, Osborne T, Chou AJ, Kim SY, Gorlick R, Hewitt SM, Khanna C.
The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC.
Oncogene. 28: 792-802, 2009.
47)  Gordon I, Paoloni M, Mazcko C, Khanna C.
The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway.
PLoS Med. 6: e1000161, 2009.
48)  Phillips B, Powers BE, Dernell WS, Straw RC, Khanna C, Hogge GS, Vail DM.
Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs.
J Am Anim Hosp Assoc. 45: 33-8, 2009.
49)  Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, Khanna C, Helman LJ.
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cancer Res. 68: 8039-48, 2008.
50)  Lee JH, Horak CE, Khanna C, Meng Z, Yu LR, Veenstra TD, Steeg PS.
Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.
Cancer Res. 68: 639-44, 2008.
51)  Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE.
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.
Cancer Res. 68: 6241-50, 2008.
52)  Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ.
Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases.
Clin. Exp. Metastasis. 25: 201-11, 2008.
53)  Khanna C.
Novel targets with potential therapeutic applications in osteosarcoma.
Current oncology reports. 10: 350-8, 2008.
54)  Kisseberth WC, Vail DM, Yaissle J, Jeglum KA, Couto CG, Ward H, Khanna C, Obradovich JE.
Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.
J. Vet. Intern. Med. 22: 83-8, 2008.
55)  Paoloni M, Khanna C.
Translation of new cancer treatments from pet dogs to humans.
Nat. Rev. Cancer. 8: 147-56, 2008.
56)  Paoloni M, Khanna C.
Clinical Trial Design and Access. In: Kirk's Current Veterinary Therapy. Volume XIV.
Elsevier; 2007. In Press. [Book Chapter]
57)  Paoloni M, Khanna C.
Clinical Trial Design and Access. In: Small Animal Oncology. Volume I.
Elsevier; 2007. In Press. [Book Chapter]
58)  Paoloni MC, Khanna C.
Comparative oncology today.
Vet. Clin. North Am. Small Anim. Pract. 37: 1023-32; v, 2007.
59)  Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES.
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
Clin. Cancer Res. 13: 4503-10, 2007.
60)  Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J.
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.
Cancer Res. 67: 32-40, 2007.
61)  Bruce B, Khanna G, Ren L, Landberg G, Jirström K, Powell C, Borczuk A, Keller ET, Wojno KJ, Meltzer P, Baird K, McClatchey A, Bretscher A, Hewitt SM, Khanna C.
Expression of the cytoskeleton linker protein ezrin in human cancers.
Clin. Exp. Metastasis. 24: 69-78, 2007.
62)  Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES.
Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma.
Mol. Cancer Res. 5: 991-9, 2007.
63)  Merlino G, Khanna C.
Fishing for the origins of cancer.
Genes Dev. 21: 1275-9, 2007.
64)  Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL.
Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Cancer Immunol. Immunother. 56: 1037-46, 2007.
65)  Ilani T, Khanna C, Zhou M, Veenstra TD, Bretscher A.
Immune synapse formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin.
J. Cell Biol. 179: 733-46, 2007.
66)  Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG, Hua E, Merino MJ, Steinberg SM, Khanna C, Steeg PS.
Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.
Cancer Res. 67: 11751-9, 2007.
67)  Werner S, Mendoza A, Hilger RA, Erlacher M, Reichardt W, Lissat A, Konanz C, Uhl M, Niemeyer CM, Khanna C, Kontny U.
Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
Cancer Chemother Pharmacol. 2007.
68)  Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt SM, Helman LJ, Khanna C, Weissman AM.
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation.
Nat. Med. 13: 1504-9, 2007.
69)  Argyle D, Khanna C.
Vail , Wtihrow , eds.
Cancer biology and metastases. In: Small Animal Clinical Oncology. Volume 4.
Philadelphia: W.B. Saunders; 2006. p. 31 [Book Chapter]
70)  Paoloni M, Khanna C.
Vail , Withrow , eds.
Molecular Diagnostics. In: Small Animal Clinical Oncology. Volume 4.
Philadelphia: W.B. Saunders; 2006. p. 134 [Book Chapter]
71)  Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, Kleiner DE, Rosenwald A, Schaefer CF, Ben-Sasson SA, Yang L, Powell J, Kane DW, Star RA, Aprelikova O, Bauer K, Vasselli JR, Maranchie JK, Kohn KW, Buetow KH, Linehan WM, Weinstein JN, Lee MP, Klausner RD, Barrett JC.
Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma.
Cancer Res. 66: 7216-24, 2006.
72)  Wan X, Shen N, Mendoza A, Khanna C, Helman LJ.
CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling.
Neoplasia. 8: 394-401, 2006.
73)  Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ, Berzofsky JA.
CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
Cancer Res. 66: 3869-75, 2006.
74)  Rusk A, Cozzi E, Stebbins M, Vail D, Graham J, Valli V, Henkin J, Sharpee R, Khanna C.
Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-I peptides, ABT-526 in pet dogs with relapsed lymphoma.
Clin. Cancer Res. 12: 7456-64, 2006.
75)  Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ.
Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.
Clin. Exp. Metastasis. 23: 227-36, 2006.
76)  Khanna C, Helman LJ.
Molecular approaches in pediatric oncology.
Annu. Rev. Med. 57: 83-97, 2006.
77)  Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C.
Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
Clin. Cancer Res. 12: 7444-55, 2006.
78)  Rassnick KM, Rodriguez CO, Khanna C, Rosenberg MP, Kristal O, Chaffin K, Page RL.
Results of a phase II clinical trial on the use of ifosfamide for treatment of cats with vaccine-associated sarcomas.
Am. J. Vet. Res. 67: 517-23, 2006.
79)  Turner AI, Hahn KA, Rusk A, Gamblin RM, Cosgrove SB, Griffice K, Khanna C.
Single agent gemcitabine chemotherapy in dogs with spontaneously occurring lymphoma.
J. Vet. Intern. Med. 20: 1384-8, 2006.
80)  Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S.
The dog as a cancer model.
Nat. Biotechnol. 24: 1065-6, 2006.
81)  Krishnan K, Khanna C, Helman LJ.
The molecular biology of pulmonary metastasis.
Thoracic surgery clinics. 16: 115-24, 2006.
82)  Thiele C, Khanna C.
Poplack , Pizzo , eds.
The Biology of Childhood Cancer. In: In Principles and Practice of Pediatric Oncology.
Philadelphia: Lippincot; 2005. p. 1-22 [Book Chapter]
83)  Khanna C, Hunter K.
Modeling metastasis in vivo.
Carcinogenesis. 26: 513-23, 2005.
84)  Wan X, Mendoza A, Khanna C, Helman LJ.
Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma.
Cancer Res. 65: 2406-11, 2005.
85)  Krishnan K, Khanna C, Helman LJ.
The biology of metastases in pediatric sarcomas.
Cancer journal (Sudbury, Mass.). 11: 306-13, 2005.
86)  Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G.
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.
Nat Med. 10: 175-81, 2004.
87)  Hansen K, Khanna C.
Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
Eur J Cancer. 40: 858-80, 2004.
88)  Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ.
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.
Nat Med. 10: 182-6, 2004.
89)  Gorlick R, Anderson P, Andrulis I, Arndt C, Beardsley GP, Bernstein M, Bridge J, Cheung NK, Dome JS, Ebb D, Gardner T, Gebhardt M, Grier H, Hansen M, Healey J, Helman L, Hock J, Houghton J, Houghton P, Huvos A, Khanna C, Kieran M, Kleinerman E, Ladanyi M, Lau C, Malkin D, Marina N, Meltzer P, Meyers P, Schofield D, Schwartz C, Smith MA, Toretsky J, Tsokos M, Wexler L, Wigginton J, Withrow S, Schoenfeldt M, Anderson B.
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
Clin. Cancer Res. 9: 5442-53, 2003.
90)  Khanna C, Vail DM.
Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers.
Curr Cancer Drug Targets. 3: 265-73, 2003.
91)  Zhang H, Merchant MS, Chua KS, Khanna C, Helman LJ, Telford B, Ward Y, Summers J, Toretsky J, Thomas EK, June CH, Mackall CL.
Tumor expression of 4-1BB ligand sustains tumor lytic T cells.
Cancer Biol. Ther. 2: 579-86, 2003.
92)  Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM, Helman LJ.
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.
Clin Cancer Res. 8: 2406-12, 2002.
93)  Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM, Helman LJ.
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.
Clin Cancer Res. 8: 2406-12, 2002.
94)  Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ.
Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis.
In Vivo. 16: 77-85, 2002.
95)  Sotiriou C, Khanna C, Jazaeri AA, Petersen D, Liu ET.
Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays.
The Journal of molecular diagnostics : JMD. 4: 30-6, 2002.
96)  Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ.
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Cancer Res. 62: 6108-15, 2002.
97)  Vail DM, Kurzman ID, Glawe PC, O'Brien MG, Chun R, Garrett LD, Obradovich JE, Fred RM, Khanna C, Colbern GT, Working PK.
STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial.
Cancer Chemother. Pharmacol. 50: 131-6, 2002.
98)  Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, Trepel J, Meltzer P, Helman L.
Metastasis-associated differences in gene expression in a murine model of osteosarcoma.
Cancer Res. 61: 3750-9, 2001.
99)  Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L.
An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential.
Clin. Exp. Metastasis. 18: 261-71, 2000.
100)  Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL.
Pretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumors.
Clin. Cancer Res. 5: 51-60, 1999.
101)  Khanna C, Lund EM, Raffe M, Armstrong PJ.
Hypomagnesemia in 188 dogs: a hospital population-based prevalence study.
J. Vet. Intern. Med. 12: 304-9, 1998.
102)  Khanna C, Lund EM, Redic KA, Hayden DW, Bell FW, Goulland EL, Klausner JS.
Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
J. Am. Vet. Med. Assoc. 213: 985-90, 1998.
103)  Khanna CM, Dubey YS, Shankar R, Kaur G.
Effects of long-term thyroid hormone suppressive treatment on the cardiac functions.
Indian heart journal. 49: 289-92, 1997.
104)  Khanna C, Boermans HJ, Wilcock B.
Fatal hypernatremia in a dog from salt ingestion.
Journal of the American Animal Hospital Association. 33: 113-7, 1997.
105)  Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS.
Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases.
Cancer. 79: 1409-21, 1997.
106)  Khanna C, Waldrep JC, Anderson PM, Weischelbaum RW, Hasz DE, Katsanis E, Klausner JS.
Nebulized interleukin 2 liposomes: aerosol characteristics and biodistribution.
J. Pharm. Pharmacol. 49: 960-71, 1997.
107)  Khanna C, Hasz DE, Klausner JS, Anderson PM.
Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies.
Clin. Cancer Res. 2: 721-34, 1996.
108)  Anderson PM, Meyers DE, Hasz DE, Covalcuic K, Saltzman D, Khanna C, Uckun FM.
In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
Cancer Res. 55: 1321-7, 1995.
109)  Khanna C, Boermans HJ, Woods P, Ewing R.
Lead toxicosis and changes in the blood lead concentration of dogs exposed to dust containing high levels of lead.
Can. Vet. J. 33: 815-817, 1992.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/7/2014.